Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2021

View Archived Issues

New CRISPR-Cas vector designs reduce vector size and increase vector titer for HIV/AIDS treatment

Studies show NNRTI MK-8507 can be used with islatravir, levonorgestrel/ethinyl estradiol

FDA approves IND for phase I/II study of Zofin in COVID-19 long haulers

FDA clears IND for Viracta's all-oral combination regimen in EBV-positive solid tumors

Positive data reported from phase Ib study of IMT-002 in T1D with HLA-DQ8 trait

Medshine Discovery patents new KHK inhibitors for NASH

Sorrento initiates dosing in U.K. phase II study of COVI-DROPS in outpatient setting

Positive phase II data for eprenetapopt plus azacitidine in TP53 mutant MDS and AML

IRF7 and PTDSS2 are therapeutic targets in HIV-1 infection

IFM Due divulges hSTING antagonists

Tyra Biosciences presents new FGFR inhibitors

R-107 shows the ability to prevent, treat and reverse established PAH in vivo

Rheos Medicines discloses MALT1 inhibitors

Apoptosis inhibitors show promise in severe TB models

Eureka initiates phase I/II ARYA-3 study of ECT-204 in liver cancer

Dicerna provides interim data from phase I study of belcesiran in AATLD

XPB shown to regulate HIV-1 transcriptional activity

Antengene obtains HREC approval in Australia for phase I study of ATG-101 in solid tumors and NHL

Addition of CF-296 to SOC leads to enhanced antibacterial activity against MSSA and MRSA isolates

Amplia reports phase I data on AMP-945

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...